OTC · NPTX
Neuropathix, Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Sep 12, 2026, 12:34 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 28.14K
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 10K
- Avg. volume
- 7.09K
Price performance
NPTX price history
1M range · 0 trading sessions · Daily adjusted prices
NPTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NPTX news
The latest Smart Investors Daily articles mentioning NPTX.
Stock researchCompany · Overview
NPTX research
Overview
Company profile and research snapshot.
Company profile
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
